Media stories about Zafgen (NASDAQ:ZFGN) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zafgen earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 47.765045101485 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the media headlines that may have impacted Accern Sentiment’s rankings:

Zafgen (NASDAQ ZFGN) traded up 1.47% on Monday, hitting $3.45. The company’s stock had a trading volume of 23,699 shares. The company has a 50 day moving average price of $3.50 and a 200-day moving average price of $4.08. Zafgen has a 1-year low of $2.89 and a 1-year high of $5.46. The company’s market capitalization is $94.43 million.

Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.03. During the same quarter in the prior year, the firm earned ($0.55) earnings per share. On average, equities analysts forecast that Zafgen will post ($2.23) earnings per share for the current fiscal year.

Several research firms have issued reports on ZFGN. Roth Capital began coverage on Zafgen in a report on Thursday, April 20th. They issued a “buy” rating and a $9.00 price target on the stock. Zacks Investment Research raised Zafgen from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a report on Wednesday, May 10th. Finally, ValuEngine cut Zafgen from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $24.25.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Zafgen (NASDAQ:ZFGN) Share Price” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-zafgen-nasdaqzfgn-share-price/1487260.html.

In other news, insider Dennis D. Kim purchased 10,000 shares of Zafgen stock in a transaction dated Tuesday, July 11th. The shares were bought at an average cost of $3.39 per share, with a total value of $33,900.00. Following the completion of the transaction, the insider now directly owns 21,443 shares in the company, valued at approximately $72,691.77. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 21.20% of the company’s stock.

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Insider Buying and Selling by Quarter for Zafgen (NASDAQ:ZFGN)

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.